-
Himax Technologies’ subsidiary Liqxtal Technology has launched the Liqxtal Pro-Eye vision-care monitor featuring Himax’s WiseEye AI facial recognition and eye-tracking technology, which was showcased at the Taiwan Healthcare+ Expo in Taipei after December 4, 2025.
-
The Pro-Eye monitor’s focus on AI-driven visual-behavior analysis, long-distance virtual viewing, and privacy shielding highlights Himax’s push into health-centered, intelligent display solutions beyond its core driver IC business.
-
We’ll now look at how WiseEye-powered Pro-Eye, blending AI sensing with eye-health benefits, may reshape Himax Technologies’ investment narrative.
AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
To own Himax, you need to believe its core display IC franchise can steadily recover while newer areas like WiseEye AI and optics become meaningful contributors. The Liqxtal Pro-Eye launch showcases that ambition but does not materially change the near term picture, where demand visibility, tariff uncertainty, and soft recent revenues and margins still look like the key swing factors.
Among recent announcements, Himax’s September showcase at the SID Vehicle Displays and Interfaces symposium stands out, as it reinforced the company’s broad automotive display portfolio across TDDI, local dimming Tcon, and OLED touch ICs. That automotive exposure, alongside WiseEye in products like Pro-Eye, sits at the heart of the main long term catalyst investors are watching as Himax works through current end market softness.
Yet even as Himax pushes deeper into AI powered displays, investors should be aware that rising operating expenses and weaker margins could…
Read the full narrative on Himax Technologies (it’s free!)
Himax Technologies’ narrative projects $1.1 billion revenue and $139.3 million earnings by 2028.
Uncover how Himax Technologies’ forecasts yield a $8.54 fair value, a 6% downside to its current price.
Eight Simply Wall St Community valuations for Himax range from about US$1.88 to US$91.18 per share, showing very different expectations. When you set those views against the current risks around demand softness and order delays, it is a reminder to weigh several perspectives before forming an opinion.
Explore 8 other fair value estimates on Himax Technologies – why the stock might be worth over 10x more than the current price!
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HIMX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
link